Legend Biotech Corp.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Legend Biotech Corp.
The drug maker pointed to a variety of key trial readouts over the course of the year, including the pivotal study of its long-acting HIV PrEP injectable and Phase III updates for Trodelvy.
BMS reiterated its 2024 focus on execution across its portfolio and R&D pipeline as it works through upcoming losses of exclusivity, and its fourth quarter revenues reflected year-end efforts to drive sales.
The cell therapy biotech will reduce its headcount from 280 to 65, with most of them – including two execs – going to Regeneron, which is paying just $5m up front to become a cell therapy player.
Sponsors still say they have no evidence the CAR-Ts cause secondary malignancy even though US FDA ordered their labels updated with a boxed warning of the adverse event. Tecartus label will not state that postmarketing secondary malignancies have been found in patients using the product.
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.